Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Aktis Oncology announced that clinical imaging and dosimetry data for AKY-2519 will be presented in two poster presentations at the 2026 ASCO Annual Meeting. The data facilitate the initial understanding of biodistribution and predicted absorbed doses in tumors and normal tissues, supporting the initiation of a Phase 1b clinical trial in mid-2026.
Key figures
- Drug Name
- AKY-2519
- Phase Of Trial
- Phase 1b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.